2nd Quarter - Report

WILLIAMS AND JENSEN, PLLC for MERCK & CO INC

Firm
Client
Income
$80,000
Expenses
—

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Payment policies for Part B prescription drugs; Rebates and co-pays for Medicare Part D drug benefits; Possible revisions in structure and operation of Medicare drug policies.

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN —
MATTHEW B HOEKSTRA —
CHERYL LYNN JAEGER Shared employee, Ofc of the Speaker and Ofc of VA 7th; Sr Policy Advisor, Majority Leader, Rep. Eric Cantor; Sr. Advisor, Majority Whip, Rep Roy Blunt; Prof Staff House Committee on E&C; Sr LA to Rep. Christopher Cox
KARINA LYNCH —
GEORGE OLSEN —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Trade (domestic/foreign) TRD

International trade issues and agreements; Monitor pending trade issues.

LobbyistCovered position, as disclosed
CHRISTOPHER W HATCHER —
KARINA LYNCH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Taxation/Internal Revenue Code TAX

Issues related to corporate tax including international tax proposals: Implementation of H.R. 1 Tax Cuts Jobs Act.

LobbyistCovered position, as disclosed
CHRISTOPHER W HATCHER —
SUSAN HIRSCHMANN COS, Rep Van Hilleary and Majority Whip
CHERYL LYNN JAEGER —
NICHOLAS KARELLAS LA to Senator Christopher Bond; Tax Counsel, Rep Lynn Jenkins
KARINA LYNCH —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1 (115th)

Health Issues HCR

Drug safety; Congressional oversight issues; Issues related to vaccines and drug pricing; Drug pricing under 340B program; General education about FDA approval policies.

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN —
CHERYL LYNN JAEGER —
KARINA LYNCH —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Budget/Appropriations BUD

Policies impacting Medicare Part D; Policies related to H.R. 1625, Consolidated Appropriations Act 2018; Policies related to H.R. 1892, the Bipartisan Budget Act of 2018.

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN New COS, Rep Van Hilleary and Majority Whip
MATTHEW B HOEKSTRA New —
CHERYL LYNN JAEGER New Shrd employee, Ofc of the Speaker & Ofc of VA 7;Sr policy adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr. LA to Rep Cox
KARINA LYNCH New Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Government Affairs

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1625 (115th), H.R. 1892 (115th)

Animals ANI

Monitor issues as they relate to animal health . Issues concerning the Animal Drug User Fee Act.

LobbyistCovered position, as disclosed
SCOTT GRAVES Deputy Chief of Staff, Rep Conaway; COS, Rep Farenthold, COS, Rep Conaway; Staff Director, House Ag Committee
CHERYL LYNN JAEGER New Shrd employee, Ofc of the Speaker & Ofc of VA 7; Sr Plicy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr LA to Rep Cox
KARINA LYNCH Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov Affairs.
ERIN BOOK MULLEN —
MATTHEW S VALESKO New —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.